Publications by authors named "V Papaianni"

: Psoriasis is a chronic inflammatory skin disease that may have a significant impact on patients' quality of life. Alongside clinical scores, treatment goals include improvements in patients' quality of life, divided into its social, working and psychosocial life aspects. Indeed, psychological impairment should always be considered in the management of moderate-to-severe psoriasis.

View Article and Find Full Text PDF
Article Synopsis
  • Novel biologics like tildrakizumab are being assessed for their effectiveness in treating psoriasis in challenging areas, focusing on patients with moderate-to-severe symptoms.
  • A study of 76 patients showed significant improvement in psoriasis severity scores after 16 weeks of treatment, highlighting the drug's potential benefits.
  • The findings suggest that tildrakizumab is effective and safe for managing difficult-to-treat psoriasis and related itching, with quick results.
View Article and Find Full Text PDF

Omalizumab is a monoclonal anti-IgE antibody which is effective in chronic spontaneous urticaria (CSU), although clinical response appears to be variable in the real-life setting. The aim of this study was to evaluate whether the response of CSU to omalizumab and disease relapse are associated with individual and/or clinical characteristics of patients. We retrospectively evaluated the clinical records of 124 patients treated with omalizumab for moderate to severe CSU refractory to antihistamines.

View Article and Find Full Text PDF

The surface receptor for advanced glycosylation end-products (RAGE) and its soluble (sRAGE) and endogenous secretory (EN-RAGE) forms belong to the superfamily of toll-like receptors and play important roles in inflammation and autoimmunity, directly or through binding with advanced glycosylation end-products (AGE) and advanced oxidation protein products (AOPP). We reviewed the literature on the role of RAGE in skin diseases. Research in this field is still rather limited (28 articles) but suggests the involvement of RAGE and RAGE-related pathways in chronic inflammatory diseases (lupus, psoriasis, atopic dermatitis, and lichen planus), infectious diseases (leprosy, -induced skin lesions), alterations of the repairing processes in diabetic skin, systemic sclerosis, and ulcers.

View Article and Find Full Text PDF